The average demand for Actemra in intravenous format increased 279 percent from June 14-25 to Aug. 2-13, according to data Vizient released Aug. 26. Simultaneously, fill rates for hospitals’ orders of the drug decreased from 99 percent to 45 percent.
Actemra was used in just 4.5 percent of all COVID-19 cases, but these cases tended to be more severe, as evidenced by higher lengths of stay, rates of intensive care unit utilization and expected mortality. More than 40 percent of COVID-19 patients who received Actemra also receive invasive ventilation.
Hospitals are experiencing a shortage of the drug. On Aug. 16, Genentech said the shortage would last “at least the next several weeks.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.